Nedosiran not checked

Novo Nordisk

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
2 active
6 in total · 2 in the EU
Targets
—
None known yet

What this is

How it works
A short strand of RNA that switches off one gene, so the body makes less of one protein.-siran: small interfering RNA WHO name stem
How it’s given
“Multiple fixed doses of DCR-PHXC by subcutaneous (SC) injection”In the company’s words, NCT04042402 on ClinicalTrials.gov
Tested for
Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Kidney Diseases, Urologic Diseases, Genetic Disease, Primary Hyperoxaluria Type 3 (PH3), Primary Hyperoxaluria Type 1, End Stage Renal Disease
Main trialPhase 3
“The proposed study is designed to provide patients previously enrolled in Phase 1 and 2 studies of DCR-PHXC and their siblings (\<18 years old) long-term access to DCR-PHXC, and to evaluate the long-term safety and efficacy of DCR-PHXC in patients with PH.”In the company’s words, NCT04042402 on ClinicalTrials.gov
Other names
DCR-PHXC

Other drugs for Primary Hyperoxaluria Type 1 (PH1)

All 4 drugs for Primary Hyperoxaluria Type 1 (PH1)

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 1 Apr 2030 Long Term Extension Study in Patients With Primary Hyperoxaluria
Phase 2Recruiting 30 Dec 2031 Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Phase 2Completed 21 Jun 2021 A Study to Evaluate DCR-PHXC in Children and Adults With Primary Hyperoxaluria Type 1 and Primary Hyperoxaluria Type 2
Phase 2Completed 5 Feb 2025 Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function
Phase 1Completed 19 Nov 2019 Study of DCR-PHXC-101 in Normal Healthy Volunteers and Patients With Primary Hyperoxaluria
Phase 1Completed 7 Sep 2021 Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Nedosiran

Following is part of Solo: you see every change to Nedosiran the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in